Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early MMR immunization during a measles outbreak in infants
NL-OMON60707Phase 4Not yet recruiting
- Sponsor
- National Institute for Public Health and the Environment
- Start
- Jul 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of measles, mumps, and rubella vaccine in measles (2 arms), sponsored by National Institute for Public Health and the Environment. Primary endpoint: Measles-specific virus neutralizing antibody concentration 4 weeks after MMR-0. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
measles, mumps, and rubella vaccine
03
Conditions
measles
Beyond the preview
Go deeper on NL-OMON60707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60707.